momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (11059)	3/6/2017 6:50:17 PM
From: scaram(o)uche	Read Replies (2) of 12215

>> what am I missing as to the bear case? << I don't have a clue. How much data do they have addressing potential immunogenicity? There are only a few anticalins in man. whereas there are millions of immunoglobulin hypervariable regions expressed. Presumably, repeat dosing in primates looked ok? Tuck, have the phase I hepcidin results been summarized anywhere? Was there repeat dosing? Are "duocalins" going to face additional issues re. immunogenicity? A few publications talk about PEGlylation to extend half-lives, but I can't find any indication of how short they are. I don't expect anyone to go out and dig up answers, particularly you, Jim. Just throwing stuff out.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next